Last reviewed · How we verify
Genetically attenuated PfSPZ Vaccine
The Genetically attenuated PfSPZ Vaccine works by introducing a weakened form of the Plasmodium falciparum parasite to stimulate an immune response against malaria.
The Genetically attenuated PfSPZ Vaccine works by introducing a weakened form of the Plasmodium falciparum parasite to stimulate an immune response against malaria. Used for Prevention of malaria.
At a glance
| Generic name | Genetically attenuated PfSPZ Vaccine |
|---|---|
| Sponsor | Sanaria Inc. |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
This vaccine uses a genetically modified form of the parasite to induce a protective immune response, which can help prevent malaria infection. The weakened parasite is designed to mimic the natural infection process, but with reduced severity, allowing the immune system to develop a targeted response without causing disease.
Approved indications
- Prevention of malaria
Common side effects
- Injection site reactions
- Fever
- Headache
Key clinical trials
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults (PHASE2)
- Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Genetically attenuated PfSPZ Vaccine CI brief — competitive landscape report
- Genetically attenuated PfSPZ Vaccine updates RSS · CI watch RSS
- Sanaria Inc. portfolio CI